

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

Claims 1-52 (Cancelled).

Claim 53 (New): A method for the preparation of a composition for inhibiting renal uptake of proteins and peptides used for therapeutic or diagnostic purposes and that may be damaging to the kidneys, comprising:

providing the combination of a first amino acid which is a lysine selected from the group consisting of D-lysine, L-lysine and poly-lysine, or a pharmaceutically acceptable salt or carboxylic acid derivative thereof; and

a second amino acid which is selected from the group consisting of arginine and ornithine, or a pharmaceutically acceptable salt or carboxylic acid derivative thereof,

wherein the first amino acid is provided in an amount of about 10-45 grams and the second amino acid is provided in an amount of about 15-45 grams per treatment.

Claim 54 (New): The method of claim 53, wherein the first amino acid is provided in an amount of about 15-35 grams and the second amino acid is provided in an amount of about 15-35 grams per treatment.

Claim 55 (New): The method of claim 53, wherein the first amino acid is provided in an amount of about 20-30 grams and the second amino acid is provided in an amount of about 20-30 grams per treatment.

Claim 56 (New): The method of claim 53, wherein the first amino acid is provided in an amount of about 25 grams and the second amino acid is provided in an amount of about 25 grams per treatment.

Claim 57 (New): The method of claim 53, wherein the second amino acid is arginine.

Claim 58 (New): A therapeutic composition for the inhibition of the renal uptake of protein or peptides used for therapeutic or diagnostic purposes that may be damaging to the kidneys, comprising one or more pharmaceutically acceptable excipients, carriers or diluents and a combination of:

a first amino acid which is a lysine selected from the group consisting of D-lysine, L-lysine and poly-lysine, or a pharmaceutically acceptable salt or carboxylic acid derivative thereof; and

a second amino acid which is selected from the group consisting of arginine and ornithine, or a pharmaceutically acceptable salt or carboxylic acid derivative thereof,

wherein the first amino acid is provided in an amount of about 10-45 grams and the second amino acid is provided in an amount of about 15-45 grams per treatment.

Claim 59 (New): The therapeutic composition of claim 58, wherein the first amino acid is provided in an amount of about 15-35 grams and the second amino acid is provided in an amount of about 15-35 grams per treatment.

Claim 60 (New): The therapeutic composition of claim 58, wherein the first amino acid is provided in an amount of about 20-30 grams and the second amino acid is provided in an amount of about 20-30 grams per treatment.

Claim 61 (New): The therapeutic composition of claim 58, wherein the first amino acid is provided in an amount of about 25 grams and the second amino acid is provided in an amount of about 25 grams per treatment.

Application No. 10/031,509  
Paper Dated: June 1, 2004  
In Reply to USPTO Correspondence of March 1, 2004  
Attorney Docket No. 702-020040

Claim 62 (New): The therapeutic composition of claim 58, wherein the second amino acid is arginine.

Claim 63 (New): The therapeutic composition of claim 58, wherein the first amino acid and the second amino acid or their respective derivatives thereof are present in about 1 L infusion fluid.

Claim 64 (New): A method for inhibiting the renal uptake of proteins or peptides used for therapeutic or diagnostic purposes in a subject, consisting of manufacturing the therapeutic composition as claimed in claim 58 and administering said therapeutic composition to the subject.